Cerdulatinib

Source: Wikipedia, the free encyclopedia.
Cerdulatinib
By mouth
Identifiers
  • 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
JSmol)
  • CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
  • InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) checkY
  • Key:BGLPECHZZQDNCD-UHFFFAOYSA-N

Cerdulatinib is a

SYK.[2]

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]

See also

References

  1. PMID 28754125
    .
  2. PMID 25253883
    .
  3. ^ "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cerdulatinib&oldid=1220609777"